Unknown NA INTERVENTIONAL 1-arm NCT03168048

Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1)

Oncologic Therapy Support Via Means of a Dedicated Mobile App - a Prospective Feasibility Evaluation

Sponsor: Heidelberg University

Conditions Breast Cancer Oncologic Disorders Pelvic Neoplasm Quality of Life Radiotherapy; Complications Satisfaction Thoracic Neoplasm

Interventions mobile application

Updated 6 times since 2017 Last updated: May 24, 2017 Started: Jul 31, 2017 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Breast Cancer and Oncologic Disorders and is currently ongoing. Heidelberg University leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2019 — Jan 2021 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jun 2019 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Jul 2017 — Jun 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany